Nr. Crt.  Nume  StatusLocatie
1    Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)            Activ, inca nu recruteazaCentrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 S.C. R.T.C. Radiology Therapeutic Center S.R.L. Otopeni, Ilfov, Romania, 075100 SC Oncopremium Team SRL Baia Mare, Maramureș, Romania, 430291 Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 Spitalul Clinic Filantropia Bucuresti, Romania, 011171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Cluj-Napoca, Romania, 400015 Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta Constanta, Romania, 900591
2Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL)    In curs de recrutareLocal Institution Not yet recruiting Bucharest, Romania, 011171 Contact: Site 0029          Local Institution Not yet recruiting Bucuresti, Romania, 022328 Contact: Site 0025          Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0028          Local Institution Not yet recruiting Floresti, Romania, 407280 Contact: Site 0027          Local Institution Not yet recruiting Suceava, Romania, 720237 Contact: Site 0026  
3Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)Activ, inca nu recruteazaNovartis Investigative Site Floresti, Cluj, Romania, 407280 Novartis Investigative Site Bucuresti, Romania, 011171 Novartis Investigative Site Bucuresti, Romania, 030463 Novartis Investigative Site Craiova, Romania, 200347 Novartis Investigative Site Iasi, Romania, 700483 Novartis Investigative Site Timisoara, Romania, 300219
4A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)Activ, inca nu recruteazaCounty Hospital Alba; Oncology Alba Iulia, Romania, 510073 „Filantropia” Clinical Hospital; Gynecological Oncology Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology Cluj-Napoca, Romania, 400006 Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Oncomed SRL Timisoara, Romania, 300239
5A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerActiv, inca nu recruteazaS.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948 Craiova, Dolj, Romania, 200347 lnstitutul Oncologic Trestiore /ID# 124943 Bucharest, Romania, 022328 Spitalul Clinic Judetean de Urgenta /ID# 124945 Cluj, Romania, 400006 Oncomed SRL /ID# 127598 Timisoara, Romania, 300239
6A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.    In curs de recrutare„Filantropia” Clinical Hospital; Gynecological Oncology Not yet recruiting Bucharest, Romania, 011191 Institute of Oncology „Prof. Dr. I. Chiricuta” Not yet recruiting Cluj-Napoca, Romania, 400015 Oncology Center Sf. Nectarie Not yet recruiting Craiova, Romania, 200347 Centrul de OncologieOncohelp Not yet recruiting Timisoara, Romania, 300239
7A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerActiv, inca nu recruteazaCenter of Oncology Euroclinic Bucharest, Romania Oncology Center Sf Nectarie Caracal, Romania Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology Cluj-Napoca, Romania Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania Oncology Center Oncolab Craiova Craiova, Romania
8A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerActiv, inca nu recruteazaInstitutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj Clinical County Hospital; Oncology Dept Cluj-Napoca, Romania, 400006 Regional Institute of Oncology Iasi Iasi, Romania, 700483
9A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerActiv, inca nu recruteazaEmergency University Bucharest Hospital; Oncology Department Bucharest, Romania, 050098 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Inst. Cluj-Napoca; Cancer Dept Cluj-Napoca, Romania, 400015 Euroclinic Center of Oncology SRL Iasi, Romania, 700106
10A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.Activ, inca nu recruteazaResearch Site Braila, Romania, 810325 Research Site Craiova, Romania, 200347 Research Site Onesti, Romania, 601048 Research Site Timisoara, Romania, 300239
11A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerIn curs de recrutare„Filantropia” Clinical Hospital; Gynecological Oncology Recruiting Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Recruiting Bucuresti, Romania, 022328 Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala Recruiting Cluj Napoca, Romania, 400015 Centrul de OncologieSfantulNectarie Recruiting Craiova, Romania, 200347
12Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)Activ, inca nu recruteazaSpitalul Clinic CF nr.2 Bucuresti Bucharest, Romania, 011464 Spitalul Municipal Ploiesti Ploiesti, Romania, 100337 SpitalulJudetean de Urgente „Sf. IoancelNou” Suceava, Romania, 720237 Spitalul Clinic JudeteanMures TgMures, Romania, 540142
13A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyActiv, inca nu recruteazaInstitut of Oncology Al. Trestioreanu Bucharest; Oncology Department Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 Euroclinic Center of Oncology SRL Iasi, Romania, 700106
14PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerActiv, inca nu recruteazaProf. Dr. I. Chiricuta Oncology Institute Cluj-Napoca, Romania Sf. Nectarie SRL Oncologie Medical Center Craiova, Romania Center of Oncology Euroclinic Iași, Romania
15A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)Activ, inca nu recruteazaProf. Dr. I. Chiricuta Institute of Oncology Active, not recruiting Cluj Napoca, Romania, 400015     Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Active, not recruiting
16Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.Activ, inca nu recruteazaResearch Site Bucharest, Romania, 013811 Research Site Bucuresti, Romania, 011171 Research Site Bucuresti, Romania, 030171 Research Site Cluj Napoca, Romania, 400015 Research Site Cluj-Napoca, Romania, 400015
17A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActiv, inca nu recruteazaFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician.
18A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerActiv, inca nu recruteazaNovartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Timisoara, Romania, 300239
19ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DActiv, inca nu recruteazaNovartis Investigative Site Bucharest, Romania, 022328 Novartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Cluj-Napoca, Romania, 400015 Novartis Investigative Site Iasi, Romania, 700106
20  A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadActiv, inca nu recruteazaProf. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347
21A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)Activ, inca nu recruteazaOncomed SRL Timisoara, Romania, 300239
22A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)In curs de recrutareNovartis Investigative Site Craiova, Dolj, Romania, 200347   Novartis Investigative Site Craiova, Dolj, Romania, 200535 Novartis Investigative Site  Bucuresti, Romania, 010991   Novartis Investigative Site Bucuresti, Romania, 011171   Novartis Investigative Site Cluj-Napoca, Romania, 400124   Novartis Investigative Site Iasi, Romania, 700106   Novartis Investigative Site Timisoara, Romania, 300239
23A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Inca nu recruteazaInstitutul Oncologic Prof. Dr. Ion Chiricuta      Cluj-Napoca, Cluj, Romania, 400015 Contact: Principal Investigator           Onco Clinic Consult SA      Craiova, Dolj, Romania, 200103 Contact: Principal Investigator           Centrul de Oncologie Sfantu Nectarie             Craiova, Dolj, Romania, 200347 Contact: Principal Investigator           Institutul Oncologic Bucuresti IOB     Bucharest, Romania, 22328 Contact: Principal Investigator    
24Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerIn curs de recrutareResearch Site       Recruiting Bucharest, Romania, 022328   Research Site       Recruiting Bucharest, Romania, 022338   Research Site       Recruiting Bucharest, Romania, 030171   Research Site       Recruiting Cluj Napoca, Romania, 400015   Research Site       Recruiting Iasi, Romania, 700483   Research Site       Recruiting Ploiesti, Romania, 100337   Research Site       Recruiting Timisoara, Romania, 300239
(Visited 13 times, 1 visits today)